ASXL1 and myelodysplastic syndrome: Thus, we screened 61 MDS patients for somatic mutations (TET2, TP53, ASXL1, EZH2, RUNX1, DNMT3A, SF3B1) by Real-Time PCR, in addition to the CC, FISH analysis, and aCGH.